Results from pharmacogenetic investigations of methylphenidate (MPH) response in
patients with ADHD are still inconsistent, especially among adults. This study investigates …

Attention-deficit/hyperactivity disorder (ADHD) is a common childhood onset
neuropsychiatric disorder with a complex and heterogeneous symptomatology. Persistence …

Several studies have evaluated the association between individual polymorphisms and
response to methylphenidate (MPH) in subjects with attention‐deficit/hyperactivity disorder …

In this pharmacogenetic study in adults with ADHD (n= 42), a stratified analysis was
performed of the association between response to methylphenidate (MPH), assessed under …

Gene polymorphisms of the 3′ untranslated region (3′‐UTR) of the dopamine transporter
(DAT1), Dopamine receptor exon 3 D4 variable number tandem repeat (DRD4VNTR) …

Methylphenidate (MPH) is a first line option in the psychopharmacologic treatment of adults
with Attention-Deficit/Hyperactivity Disorder (ADHD). However, there is a considerable …

OBJECTIVE: This study examines the potential role of candidate genes in moderating
treatment effects of methylphenidate (MPH) in attention-deficit/hyperactivity disorder …

Methylphenidate (MPH) is the most frequently used pharmacological treatment in children
with attention-deficit/hyperactivity disorder. However, a considerable interindividual …

OBJECTIVE: Because of significant individual variability in attention-deficit/hyperactivity
disorder (ADHD) medication response, there is increasing interest in identifying genetic …

OBJECTIVE: The authors explored genetic moderators of symptom reduction and side
effects in methylphenidate-treated preschool-age children diagnosed with attention …